Actively Recruiting
Genetics of the Acute Response to Oral Semaglutide
Led by Medical University of Bialystok · Updated on 2025-03-26
1000
Participants Needed
1
Research Sites
173 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study aims to investigate the genetic basis of the response to short-term (3 months) orally administered semaglutide treatment, in terms of improving metabolic parameters, including the hormonal response to a standardized meal, and changes in body composition and liver steatosis. In the study, parameters such as fasting and 2-hour glucose during OGTT, HbA1c, body fat mass, body weight, total cholesterol, HDL and LDL, triglycerides, HOMA-IR, Matsuda Index and liver steatosis will be assessed. All the patients will undergo genome-wide genotyping. Moreover, in a subset of participants, muscle and fat biopsies will be performed, before and after the treatment, and liver, muscle and pancreas fat content will be assessed using MRI.
CONDITIONS
Official Title
Genetics of the Acute Response to Oral Semaglutide
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided informed consent before any study procedures
- Aged between 18 and 65 years
- Body mass index (BMI) over 30 kg/m2, or over 27 kg/m2 if diagnosed with prediabetes according to American Diabetes Association criteria
You will not qualify if you...
- Diagnosed with serious chronic diseases including ischemic heart disease, heart failure (NYHA class III-IV), severe renal insufficiency (eGFR <30 ml/min), severe liver diseases, inflammatory bowel disease, diabetic gastroparesis, cancer within the last five years, chronic obstructive pulmonary disease, or major mental illness
- Use of medications known to cause significant weight gain or loss
- History of bariatric or stomach surgery affecting drug absorption
- History of idiopathic acute pancreatitis
- Personal or family history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid cancer
- Women who are pregnant, breastfeeding, planning pregnancy, or not using highly effective contraception
- Known or suspected allergy to the study drug
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical Research Centre, Medical University of Bialystok
Bialystok, Podlaskie Voivodeship, Poland, 15-276
Actively Recruiting
Research Team
L
Lukasz Szczerbinski, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here